$NVCN Posted March 3.17.2018 Gagnon Advisors LLC raised its stake in Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) by 50.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,829,482 shares of the medical equipment provider’s stock after acquiring an additional 610,376 shares during the quarter. Neovasc Inc (US) makes up 0.8% of Gagnon Advisors LLC’s holdings, making the stock its 28th biggest position. Gagnon Advisors LLC owned approximately 2.32% of Neovasc Inc (US) worth $1,098,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Hudson Bay Capital Management LP purchased a new position in Neovasc Inc (US) in the fourth quarter valued at about $6,213,000. 41.49% of the stock is owned by institutional investors.

Neovasc Inc (NASDAQ NVCN) traded up $0.02 during midday trading on Friday, hitting $0.13. 105,803,590 shares of the stock traded hands, compared to its average volume of 25,067,464. Neovasc Inc has a one year low of $0.10 and a one year high of $2.12. The company has a market capitalization of $8.77, a price-to-earnings ratio of 0.56 and a beta of 0.52.

A number of research analysts have weighed in on the stock. ValuEngine cut shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut shares of Neovasc Inc (US) from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $1.05 target price on shares of Neovasc Inc (US) in a research note on Friday, January 19th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.95.

Neovasc Inc (US) Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.